What question did this study set out to answer?

The aim is to examine the differences and effectiveness of potassium-competitive acid blockers compared to proton pump inhibitors.

synapse

⌘+K

synapse

⌘+K

June 3, 2026Open Access

Potassium-competitive acid blockers: Clinical pearls and practical insights

Key Points

The aim is to examine the differences and effectiveness of potassium-competitive acid blockers compared to proton pump inhibitors.
Reviewed current literature on potassium-competitive acid blockers and vonoprazan.
Discussed evidence supporting their clinical use and effectiveness.
Outlined indications and future research directions.
Vonoprazan is the only P-CAB approved in the U.S., showing superior efficacy in specific cases compared to PPIs.
P-CABs offer alternative treatment options, particularly for patients unresponsive to traditional therapy.
Future studies are underway to further explore the clinical applications of P-CABs.

Abstract

Potassium-competitive acid blockers (P-CABs) are a new class of acid-suppressing drugs; to date, only one of them (vonoprazan) has been approved for use in the United States. The authors of this article review how P-CABs (and vonoprazan in particular) differ from proton pump inhibitors (PPIs), evidence supporting their effectiveness, indications for vonoprazan, and ongoing and future studies.

Bookmark

View Full Paper